Share on LinkedInShare on LinkedIn

ARTICLE · 09 SEPTEMBER 2016

Evolution Of The Common General Knowledge: Humanized Antibody Claims Upheld At The Canadian Patent Appeal Board

Applicants prevailed in the recent Commissioner's Decision Re Kaisha from the PAB and can now claim humanized antibodies in cases where the antigen has been well characterized...

CanadaIntellectual Property

Applicants prevailed in the recent Commissioner's Decision Re Chugai Seiyaku and Kabushiki Kaisha (CD 1398, hereinafter "Kaisha") 1 from the Patent Appeal Board ("PAB") and can now claim humanized antibodies in cases where the antigen has been well characterized, even in the absence of complementarity determining region ("CDR") sequences or evidence that the humanized antibodies had been made as of the filing date. This decision marks another incremental step towards modernizing Canadian examination practice regarding antibodies, and it could also have broader implications.

Institut Pasteur and Sloan-Kettering: The Rigid Rule

Traditionally, patent examiners have blocked applicants from pursuing claims to non-exemplified antibodies since the 1995 decision Re Institut Pasteur Application (CA 1206) 2. In Institut Pasteur, the PAB rejected claims to non-exemplified monoclonal antibodies, holding that making the claimed antibodies would have required "considerable and

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from